Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference25 articles.
1. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse;Sternberg;Cancer,1989
2. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract—a Northern California Oncology Group Study;Harker;J Clin Oncol,1985
3. Long-term follow-up of phase II intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Saxman;J Clin Oncol,1997
4. A randomised trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors—a Medical Research Council study;Mead;Br J Cancer,1998
5. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin); effect on the primary bladder lesion;Scher;J Urol,1988
Cited by 395 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Research Progress of Neoadjuvant Chemotherapy in Advanced Bladder Cancer;annals of urologic oncology;2024-08-20
2. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer;European Urology Oncology;2024-06
3. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer;Advances in Oncology;2024-05
4. DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer;Scandinavian Journal of Urology;2024-02-26
5. A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues;Frontiers in Immunology;2024-02-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3